In previous studies, we found modestly decreased and increased risks of second breast cancer events with the use of statins and antibiotics, respectively, after adjustment for surveillance mammography. We evaluated detection bias by comparing receipt of surveillance mammography among users of these 2 disparate classes of medication. Adult women diagnosed with early-stage breast cancer during 1990-2008 (n = 3,965) while enrolled in an integrated health-care plan (Group Health Cooperative; Washington State) were followed for up to 10 years in the Commonly Used Medications and Breast Cancer Outcomes (COMBO) Study. Categories of antibiotic use included infrequent (1-3 dispensings/12 months) and frequent (≥4 dispensings/12 months) use, and categories of statin use included less adherent (1 dispensing/6 months) and adherent (≥2 dispensings/6 months). We examined associations between medication use and surveillance mammography using multivariable generalized estimating equations and evaluated the impact of adjusting for surveillance within Cox proportional hazard models. Frequent antibiotic users were less likely to receive surveillance mammography (odds ratio (OR) = 0.90, 95% confidence interval (CI): 0.82, 0.99) than were nonusers; no association was found among infrequent users (OR = 0.96, 95% CI: 0.90, 1.03). Adherent statin use was associated with more surveillance compared with nonuse (OR = 1.11, 95% CI: 1.01, 1.25), but less adherent statin use was not (OR = 1.03, 95% CI: 0.81, 1.31). No difference in associations between medications of interest and second breast cancer events was observed when surveillance was removed from otherwise adjusted models. The influence of detection bias by medication use warrants further exploration. breast cancer; cancer survivorship; detection bias; epidemiologic methods
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In previous studies, we found modestly decreased and increased risks of second breast cancer events with the use of statins and antibiotics, respectively, after adjustment for surveillance mammography. We evaluated detection bias by comparing receipt of surveillance mammography among users of these 2 disparate classes of medication. Adult women diagnosed with early-stage breast cancer during 1990-2008 (n = 3,965) while enrolled in an integrated health-care plan (Group Health Cooperative; Washington State) were followed for up to 10 years in the Commonly Used Medications and Breast Cancer Outcomes (COMBO) Study. Categories of antibiotic use included infrequent (1-3 dispensings/12 months) and frequent (≥4 dispensings/12 months) use, and categories of statin use included less adherent (1 dispensing/6 months) and adherent (≥2 dispensings/6 months). We examined associations between medication use and surveillance mammography using multivariable generalized estimating equations and evaluated the impact of adjusting for surveillance within Cox proportional hazard models. Frequent antibiotic users were less likely to receive surveillance mammography (odds ratio (OR) = 0.90, 95% confidence interval (CI): 0.82, 0.99) than were nonusers; no association was found among infrequent users (OR = 0.96, 95% CI: 0.90, 1.03). Adherent statin use was associated with more surveillance compared with nonuse (OR = 1.11, 95% CI: 1.01, 1.25), but less adherent statin use was not (OR = 1.03, 95% CI: 0.81, 1.31) . No difference in associations between medications of interest and second breast cancer events was observed when surveillance was removed from otherwise adjusted models. The influence of detection bias by medication use warrants further exploration. breast cancer; cancer survivorship; detection bias; epidemiologic methods Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; COMBO, Commonly Used Medications and Breast Cancer Outcomes; GHC, Group Health Cooperative; HR, hazard ratio; OR, odds ratio; SBCE, second breast cancer event; SEER, Surveillance, Epidemiology, and End Results.
Biases are a limitation of observational studies (1, 2) . Detection bias occurs when exposure groups differ systematically in terms of the measurement or diagnosis of the outcome (3) . Detection bias is commonly cited as a potential limitation in observational studies of medication use and cancer outcomes (4) (5) (6) (7) (8) . Detection bias is hypothesized, in part, because of observed differences between individuals who initiate and adhere to the use of certain medications and those who do not (9) . Specifically, patients who adhere to preventive therapies (e.g., statins) are more likely to engage in health-seeking behaviors than those who do not adhere (10) . Alternatively, but in support of a potential bias, ill patients who often use numerous medications sometimes forego preventive services such as influenza vaccination (11) and cancer screening (12) . Differential screening rates by medication use could then alter the likelihood and timing of cancer diagnoses between groups.
There is little or no information on whether breast cancer pharmacoepidemiologic studies suffer from detection bias. One study showed that adherent statin users were more likely to receive screening mammograms than women with only 1 pharmacy dispensing of statin medication (10) . Another study found only a borderline association between statin adherence and use of mammography (9) . Understanding this bias is important, given the number of studies conducted on commonly used medications and breast cancer risk and recurrence (13) (14) (15) (16) (17) (18) . Investigators in these studies often do not consider screening (15) (16) (17) or surveillance (13, 14, 18) in their analyses.
As a first step in exploring detection bias by medication exposure, we conducted parallel investigations of the receipt of surveillance mammography among users of 2 disparate classes of commonly used medication-statins and antibiotics-in an already established cohort of women with early-stage breast cancer. These 2 classes of medication were previously studied with respect to breast cancer risk and recurrence (4, (19) (20) (21) (22) (23) , and there is a history of controversy as to whether these classes are associated with increases (antibiotics) and decreases (statins) in risk. In previous analyses adjusting for surveillance mammography, our findings showed modest associations suggestive of decreased risk of second breast cancer events (SBCEs) with statin use (19) and increased SBCE risk with frequent antibiotic use (20) . These medications are used for different purposes: prevention versus symptomatic treatment. We hypothesized that statin adherers are more health-conscious patients than statin nonusers (9) and thus are more likely to receive surveillance mammography. We hypothesized that frequent antibiotic users are sicker patients and therefore less likely to receive surveillance mammography. To further explore detection bias, we estimated the associations between the medications of interest and SBCEs with and without adjustment for adherence to surveillance mammography.
METHODS

Study population
The parent study, the Commonly Used Medications and Breast Cancer Outcomes (COMBO) Study, was described previously (19, 20) . Briefly, COMBO was conducted within the Group Health Cooperative (GHC), a mixed-model healthcare delivery system that provides comprehensive health care on a prepaid basis to approximately 600,000 enrollees throughout western Washington State and parts of Idaho. The COMBO cohort (n = 4,216) included women aged ≥18 years who were diagnosed with American Joint Committee on Cancer (24) stage I or stage II incident breast cancer between 1990 and 2008 (determined via the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) Program registry) and were enrolled in GHC's integrated group practice for at least 1 year before and after (unless they died) breast cancer diagnosis. The GHC Institutional Review Board approved this study.
Data collection
Data were collected from medical record review, the Seattle-Puget Sound SEER Program registry, administrative databases, and GHC's Breast Cancer Screening Recruitment and Reminder survey during the period ranging from 1 year prior to diagnosis through the earliest of death, disenrollment from GHC, or the end of the study (25) . Data on demographic characteristics, enrollment, smoking status, inpatient and outpatient medical encounters (including diagnoses), type of provider seen during outpatient visits, and death are included in GHC administrative databases (26) . We captured information on outpatient pharmacy dispensings for oral antibiotics and statins from the GHC pharmacy database, which contains records of all prescriptions dispensed at GHC's pharmacies as well as claims received from contracting pharmacies (26) . Information on incident breast cancer treatment and details on SBCEs were abstracted from medical charts. Information on mammography and breast magnetic resonance imaging indications and examination dates was obtained from GHC administrative databases (from 1996 forward) and medical charts (prior to 1996). Menopausal status was ascertained from the Breast Cancer Screening Recruitment and Reminder survey. We used the Seattle-Puget Sound SEER Program registry to obtain data on incident breast cancer characteristics (24) .
Surveillance procedures. We defined surveillance as a postdiagnosis mammogram or breast magnetic resonance imaging among women with no reported symptoms at the time of the examination and where the indication was designated as screening by the radiologist (27, 28) . Surveillance procedures also included short-interval follow-up examinations, unless they were less than 9 months after a diagnostic examination (27, 28) . Since magnetic resonance imaging examinations comprised only 0.7% of procedures, we refer to surveillance procedures as surveillance mammography.
We evaluated surveillance during sequential 12-month periods beginning at month 7 after diagnosis of the incident breast cancer (12, 29, 30) . We excluded the first 6 months after diagnosis, since women were likely to be undergoing active treatment during this time (12, 29, 30) . We examined each 12-month period over a 10-year follow-up period and assigned a dichotomous indicator for whether women received at least 1 surveillance procedure. To be included in a given 12-month surveillance year, women were required to be enrolled, alive, and free of SBCEs for the entire 12-month period.
Second breast cancer events. SBCEs were defined as the first of a ductal carcinoma in situ or invasive cancer of the ipsilateral (recurrence) or contralateral (second primary) breast or at any regional or distant site (19) .
Current medication exposure. Our main medication exposure categories were based on "current" use or use within each unique surveillance year (Figure 1 ). If a woman met the exposure definition (see below) at any point during a surveillance year, she was classified as being exposed for that entire surveillance year. Exposure status was then reevaluated during each subsequent year. We used current use for our main analyses because any relationship between medication use and health-care-seeking behavior is most likely observable during the surveillance year of interest. Healthcare-seeking behavior attributable to exposure in year 1 may not reflect behavioral patterns in year 10.
Definitions of antibiotic exposure. On the basis of a consensus group of prescribers and pharmacists, frequent antibiotic users were defined as women with 4 or more pharmacy dispensings of any oral antibiotic in a 12-month period (20) .
Infrequent antibiotic users consisted of women with 1-3 antibiotic dispensings in a 12-month period. All antibiotic exposures were ascertained within any moving 12-month period after diagnosis.
Definitions of statin exposure. Based on prior work by Brookhart et al. (10) , we defined "adherent statin users" as women with 2 or more pharmacy dispensings of any statin in a 6-month period. "Less adherent statin users" included women with 1 statin dispensing in a 6-month period ( Figure 1 ). All statin exposures were ascertained within any moving 6-month period after diagnosis.
Secondary exposures. In common with the pharmacoepidemiology literature (20, 31, 32) , a participant was included in an exposure category when she met the definition of use and remained there even if she discontinued use ( Figure 2 ). We refer to this exposure classification as "ever/never" use and evaluated it in secondary analyses. We required subjects to meet the exposure definition (see above) for at least 8 months of the surveillance year for exposure status to change in that year; otherwise, exposure status changed in the next surveillance year. We tested the sensitivity of this threshold by changing the requirement that subjects be exposed for at least 6 months of the surveillance year. Exposed individuals were only allowed to transition from nonuse to higher exposure categories over time. Exposure status was carried forward to subsequent surveillance years and remained constant once the highest exposure category had been reached.
Covariates. We selected covariates that would probably be included in breast cancer pharmacoepidemiologic studies (19, 20) examining the use of these medication classes in relation to breast cancer outcomes. We defined and measured 3 types of covariates: 1) static covariates assessed only once at diagnosis (variable status remained fixed over time); 2) covariates updated in each surveillance year (variable status was independently assessed during each surveillance year and did not carry over to subsequent years); and 3) timevarying covariates assessed throughout the entire study period (variable status was updated when status changed and was carried over to subsequent surveillance years).
We considered the following covariates measured around the time of diagnosis to be static: menopausal status (33), body mass index (weight (kg)/height (m) 2 ), smoking status, breast cancer characteristics (diagnosis year, tumor stage (24), hormone receptor status), and primary surgical treatment. We modeled age, type of provider seen, and years of follow-up after treatment as covariates updated each surveillance year. Charlson Comorbidity Index (CCI) (34) score was timevarying, where women could only transition from lower to higher scores over time. Type of provider seen during outpatient visits within each surveillance year included 4 categories: oncologist, primary-care provider, both, or neither. For nonstatic covariates, we required a person to be in a particular covariate category (e.g., CCI score ≥2) for at least 8 months of the surveillance year in order for covariate status to change in that year; otherwise, covariate status changed in the next surveillance year (similar to our ever/never secondary exposure). For example, if a woman's CCI score changed from 1 to ≥2 at month 10 of a surveillance year, her score would remain 1 in that surveillance year and change to ≥2 in the subsequent surveillance year.
Data analysis
In the primary analyses, we evaluated whether current medication use was associated with receipt of yearly surveillance mammography over a 10-year period. Antibiotic use and statin use were modeled separately, and medication classes were not mutually exclusive. Ever use of medication versus never use was evaluated in secondary analyses. Nonusers were the reference category for all analyses. To account for the correlation among time periods of observation contributed by each woman, we used repeated-measures generalized estimating equation regression models to estimate odds ratios and robust 95% confidence intervals (35) . Similar to the approach taken in other investigations of mammography utilization over time (12, 36, 37) , we used a logit link based on a binomial distribution with an unstructured correlation covariance. All models were adjusted for the covariates described above.
Subjects were censored at 10 years of follow-up or the earliest of death, disenrollment, or diagnosis of an SBCE, including recurrence or a second primary breast cancer (38) . We required women to have complete data for the entire surveillance year in order to be included for that year (i.e., subjects must have been alive and not censored). We excluded 251 of the 4,216 eligible women because they did not complete the entire year 1 surveillance interval (108 SBCEs, 66 deaths, 63 end of study, 14 disenrolled); this resulted in a final cohort of 3,965 women.
Because statins were not in widespread use until the mid1990s, we conducted a sensitivity analysis in which we reestimated the association between statins and surveillance for the periods of 1990-1994 and 1995 onward.
In prior multivariable Cox proportional hazards that included adjustment for receipt of surveillance mammography in the 12 months prior to the event (time-varying), we estimated the risk of SBCEs according to frequent antibiotic use (20) and statin use (19) . We estimated these same models without adjustment for surveillance.
All analyses were performed using Stata/IC 12 software (StataCorp LP, College Station, Texas). 
RESULTS
Characteristics of the study cohort by medication use for surveillance year 1 are shown in Table 1 . Approximately 18% of the women were frequent antibiotic users and 31% were infrequent users. Frequent antibiotic users were more likely to have a higher body mass index and CCI score, to be diagnosed in earlier years, to have stage II initial breast cancer, and to undergo mastectomy compared with nonusers. Infrequent antibiotic users were similar to nonusers except that infrequent users were more likely to have higher CCI scores and earlier-stage breast cancers. We observed minimal changes in patient characteristics in subsequent surveillance years (data not shown). Frequent antibiotic use declined to 12%-14% in years 2-10.
Fewer than 1% of women were less adherent statin users in year 1 (Table 1) , and the prevalence of less adherent statin use remained low throughout the study period. Therefore, we only describe the characteristics of adherent statin users. In year 1, 10% of women were adherent statin users. Adherent statin users were more likely to have outpatient visits with both oncologists and primary-care practitioners, higher CCI scores, and higher body mass indexes; more likely to be older, postmenopausal, smokers, and diagnosed with their incident breast cancer more recently; and more likely to have hormone receptor-positive tumors compared with nonusers. We observed minimal changes in patient characteristics in subsequent surveillance years, but the percentage of adherent statin users steadily increased by 1%-2% each year, to 24% by year 10 (data not shown).
The unadjusted overall results indicated that 79% of women received surveillance in year 1, but rates decreased to 63% by year 10. Unadjusted surveillance rates are given by medication exposure category for each year in Figures 3  and 4 .
In the multivariable models, frequent antibiotic use was associated with lower odds of surveillance mammography in comparison with nonuse (odds ratio (OR) = 0.90, 95% confidence interval (CI): 0.82, 0.99), but infrequent antibiotic use was not (Table 2) . Adherent statin users demonstrated higher odds of mammography during follow-up compared with nonusers (OR = 1.11, 95% CI: 1.01, 1.25). Less adherent statin use was not associated with receipt of surveillance mammography compared with nonuse, though there were very few women in this exposure category. The adjusted estimates for adherent statin users changed in direction when the CCI was added to the simple age-and yearadjusted model (OR = 0.94 moving to OR = 1.05). Trivial differences were observed in sensitivity analyses of statin use during 1990-1994 (prior to widespread use) and from 1995 onward.
Odds ratios for other patient characteristics are displayed in Appendix Table 1 . Covariates associated with more receipt of surveillance included: number of visits to an oncologist, estrogen receptor-negative/progesterone receptor-negative tumors, and receipt of endocrine therapy. Younger (<34 years) and older (>75 years) age, CCI score ≥1 versus zero, American Joint Committee on Cancer stage II versus stage I, mastectomy, and breast-conserving surgery without radiation versus breast-conserving surgery with radiation were associated with being less likely to undergo surveillance mammography. In secondary analyses of ever/never medication exposure, antibiotic use was associated with lower odds of mammography during follow-up compared with nonuse (for infrequent users, OR = 0.92, 95% CI: 0.83, 1.02; for frequent users, OR = 0.82, 95% CI: 0.72, 0.93), though the finding was significant only for frequent users. Adherent statin users had nonsignificant but slightly higher odds of mammography receipt (OR = 1.08, 95% CI: 0.97, 1.21) than nonusers. We found no association between less adherent statin use and receipt of surveillance mammography in comparison with nonuse. These findings were robust to sensitivity analyses changing exposure requirements from ≥8 months to ≥6 months of the surveillance year in order for exposure status to change during that surveillance year.
In multivariable models adjusting for surveillance mammography, results suggested a modestly increased risk of SBCE (hazard ratio (HR) = 1.15, 95% CI: 0.88, 1.50) among frequent antibiotic users compared with nonusers (20) . The hazard ratio and 95% confidence interval were exactly the same when surveillance mammography was removed from the multivariable model for frequent antibiotic use (HR = 1.15, 95% CI: 0.88, 1.50). In the fully adjusted model, the hazard ratio for SBCE was 0.82 (95% CI: 0.62, 1.08) for statin users vs. nonusers (19) . Removal of surveillance from the model did not change these estimates (HR = 0.82, 95% CI: 0.62, 1.08). Adherence to surveillance differed little by SBCE status: 46% of women who eventually experienced an SBCE and 43% of women with no SBCE adhered to yearly surveillance for at least 80% of the study follow-up period; 28% and 35%, respectively, adhered for 50%-80% of the follow-up period (20) .
DISCUSSION
We evaluated the potential for detection bias among women exposed to 2 classes of medication that are used for different purposes (prevention vs. symptomatic treatment) and are hypothesized to have opposite associations with the risk of incident breast cancer and SBCE. In our study, we observed that frequent antibiotic users were less likely to receive surveillance mammography during follow-up than were nonusers. On the contrary, adherent statin users were more likely to receive surveillance mammography than nonusers. These findings provide evidence of detection bias in breast cancer pharmacoepidemiologic studies and suggest that detection bias may differ by type and extent of medication exposure in women with early-stage breast cancer. However, estimates of association between the medications of interest and SBCEs did not differ by adjustment for surveillance mammography. This is probably due both to the relatively modest relationship between the medications and mammography and to relatively high long-term surveillance rates (39) that differed only slightly by SBCE status (20) . While this apparent bias cannot be ruled out, it may have little influence on the observed risk estimates in this cohort of early-stage breast cancer survivors.
There may be various explanations for the observed associations between medication use and surveillance mammography. Healthy user bias may contribute to the relationship between statin use and adherence to mammography. Women with positive health-care-seeking behaviors, such as adherence to preventive therapies like statin use, are likely to also seek other preventive services (40) . It would then follow that these women are more likely to have SBCEs detected or to have them detected earlier compared with nonusers or nonadherers. A similar pattern would be expected for incident breast cancer if our results can be extended to screening in disease-free women. Higher mammography rates and therefore more detection of disease among statin users could spuriously increase risk estimates in comparison with less adherent users and nonusers. However, the previously observed reductions in risk of breast cancer recurrence among statin users (13, 18, 19, 41) and null associations or slight reductions in risk of incident breast cancer with statin use (4, 42) do not support the possibility of a spuriously increased risk of breast cancer with statin use due to detection bias. Alternatively, detection bias could spuriously lower risk estimates associated with advanced/late-stage tumor characteristics and breast cancer mortality, because a higher rate of mammography use among adherent statin users could lead to a stage shift where women diagnosed with screen-detected breast cancer have early-stage tumors or less progression of recurrence compared with women diagnosed with symptomdetected breast cancer. We observed no difference in tumor stage at incident breast cancer diagnosis by statin use in our prior work (31), but Coogan et al. (43) noted detection bias as a possible explanation for their observed higher odds of in-situ and early-stage breast cancer with statin use as compared with odds ratios for more invasive cancer. However, studies finding a reduced risk of breast cancer mortality among statin users support the theory of stage shift due to detection bias (44, 45) .
Opposite of healthy users, women seeking symptomatic care, such as those who frequently use antibiotics, may receive less surveillance because they are sicker and thus less concerned with preventive services. Receipt of surveillance mammography among breast cancer survivors reaches a threshold at which women with more visits and comorbid conditions receive fewer mammograms (12). Keating et al. (12) suggested that patients reach a point where they are so ill they forgo surveillance mammography. Supporting this hypothesis is a study by Jackson et al. (11) which demonstrated that seniors with limited functional status are less likely to seek influenza vaccination. We found that CCI score was an important covariate in our adjusted models and changed the direction and magnitude of our risk estimates for adherent statins, thereby also supporting the potential role of comorbidity burden in the receipt of preventive services.
With the observed lower odds of adherence to mammography among frequent antibiotic users, one could hypothesize that detection bias may result in spurious findings suggesting that antibiotics are associated with a reduced risk of breast cancer. However, studies on antibiotic use and breast cancer risk and outcomes do not support this theory. One prior study conducted at GHC found that increasing numbers of cumulative days of antibiotic use were associated with increased risk of incident breast cancer and fatal breast cancer (21), but this association was not supported in a subsequent study carried out in a different and larger population (23) . We found a suggestion of a modest increase in risk of SBCEs among frequent antibiotic users compared with nonusers (20) . Additionally, antibiotic use was not associated with less favorable tumor profiles (22) .
We are unaware of any study that has directly examined the association between medication exposures and mammography use among breast cancer survivors, and only limited information exists in women without a history of breast cancer. Our findings on surveillance may not be generalizable to primary screening for incident cancers. This is noteworthy because adherence to screening guidelines is lower than is advised in surveillance recommendations (46, 47) . COMBO Study data extended back 1 year prior to diagnosis, so we could not fully consider the associations of precancer medication use with screening (4, 21) . In a prior study on the association between antibiotic use and incident breast cancer characteristics among older women at GHC, women with higher levels of antibiotic use were more likely to receive screening mammography during the 2 years prior to diagnosis (22) . We located 2 studies that evaluated receipt of mammography screening among statin users (9, 10). Brookhart et al. (10) reported that among Medicare enrollees, adherent statin users-defined as persons with ≥2 statin dispensings in a 12-month ascertainment period-were 22% more likely to receive screening mammograms than persons dispensed only 1 statin prescription. Brookhart et al. attributed the higher level of screening mammography among statin adherers to healthy user bias (10) . In another study conducted in Canada, Dormuth et al. (9) found only a small increase in the likelihood of receiving screening mammograms among more adherent statin users compared with those less adherent. This analysis was not restricted in age and may have included women for whom screening mammography was not recommended. It is also possible that health-care providers are more likely to recommend mammography among users of these medications because of the numerous published studies on their association with breast cancer.
This population-based study had numerous strengths. We used administrative databases and medical charts to obtain complete longitudinal data on medication use, covariates, SBCE, and surveillance mammography for up to 10 years. We evaluated an insured population with coverage for preventive services, so it is less likely that utilization was influenced by cost or lack of access. However, there are limitations to note. Our study was conducted in 1 cohort of persons enrolled in a single health-care plan. Our hypotheses should be tested across different settings, populations, and medication prevalences. It was beyond the scope of our study to determine whether stage shift in surveillancedetected cancers differed by medication use. It is also possible that the medication leading to differential rates of detection could influence the visibility of the tumor or could influence the rate of tumor growth; so even if users and nonusers were screened at the same intervals, the tumors would be of different sizes. While this study suggests that breast cancer pharmacoepidemiologic studies can be confounded by detection bias, we did not address methods for minimizing this bias or the degree of bias necessary to appreciably alter risk estimates. Our choice to censor women at SBCE may have resulted in some missed surveillance. Last, there was potential for misclassification of medication exposure if patients were prescribed medication but did not fill the prescription at a pharmacy or ultimately did not ingest the medication, or if patients who received medications at non-GHC pharmacies did not submit a claim to GHC. However, this was minimized in our study, because we required more than 1 dispensing during a short time period, and GHC enrollees obtain 97% of their medications at GHC pharmacies (48, 49) . c Generalized estimating equations model with adjustment for years of follow-up, year of diagnosis, age, menopausal status, body mass index, smoking status, Charlson Comorbidity Index score, type of provider seen, tumor stage, primary treatment for the initial breast cancer, and hormone receptor status.
In summary, our results suggest that studies investigating the association between common medications, such as antibiotics and statins, and breast cancer outcomes may be subject to detection bias. Our evaluation of potential detection bias may inform methodological approaches to the design and interpretation of breast cancer research, as well as spur discussion on the use of bias analysis in cancer pharmacoepidemiologic studies (50, 51) . Additional research on differences in detection of breast cancer outcomes with concurrent use of multiple medications in breast cancer survivors is necessary to confirm our findings. Given the large number of pharmacoepidemiologic studies on incident cancer risk, future research on detection bias (i.e., primary screening) by medication use in nondiseased populations is warranted. Our results also raise questions about potential detection bias in studies of other site-specific cancers, such as colorectal cancer and prostate cancer. While we suggest that detection bias may be reduced by adjusting for surveillance, ongoing surveillance is a complex variable to model. One approach is to adjust for time-varying surveillance received (yes/no) during the 12 months prior to events (i.e., the interval between recommended surveillance mammograms) (19, 20) . However, we did not observe any differences in associations between the medications of interest and SBCEs according to adjustment for surveillance (i.e., with or without adjustment) when it was modeled as a time-varying covariate. This suggests that further investigation is necessary to determine whether adjustment is required and, if so, the optimal approach for modeling surveillance mammography so that it adequately adjusts for potential detection bias. Further, the appropriate lead time/interval for this type of adjustment for screening in disease-free populations is somewhat less clear (52) . At a minimum, surveillance patterns by exposure status should be explored prior to or during the study design and analytical phases of studies. Finally, investigating the influence of detection bias on study findings, such as determining the degree of bias that needs to exist in order to affect risk estimates, is warranted and should be incorporated as a follow-up to our results.
